Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
D. Western Therapeutics Institute's revenue for the
three
months ended in Dec. 2025 was 円0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was 円91.59 Mil.
D. Western Therapeutics Institute's Revenue per Share for the
three
months ended in Dec. 2025 was 円0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円1.99.
Warning Sign:
D. Western Therapeutics Institute Inc revenue per share has been in decline for the last 5 years.
During the past 13 years, D. Western Therapeutics Institute's highest 3-Year average Revenue per Share Growth Rate was 60.30% per year. The lowest was -24.80% per year. And the median was 9.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
D. Western Therapeutics Institute Revenue Related Terms
D. Western Therapeutics Institute Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, D. Western Therapeutics Institute's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D. Western Therapeutics Institute Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Revenue distribution charts can be found below:
* The bar in red indicates where D. Western Therapeutics Institute's Revenue falls into.
D. Western Therapeutics Institute Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円91.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute (TSE:4576) has a Revenue of 円91.59 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on D. Western Therapeutics Institute and its competitors.
Is D. Western Therapeutics Institute's Revenue too high?
D. Western Therapeutics Institute's current Revenue is 円91.59 Mil. Overall, D. Western Therapeutics Institute has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Revenue compare to VRTX and REGN?
D. Western Therapeutics Institute's Revenue of 円91.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on D. Western Therapeutics Institute and its competitors. D. Western Therapeutics Institute's current Revenue is 円91.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (TSE:4576) is currently considered Fairly Valued. The stock's GF Value™ is 円68.02, compared to a current price of 円75.00 — trading 10.3% above its estimated fair value. The current Revenue is 円91.59 Mil. D. Western Therapeutics Institute's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For D. Western Therapeutics Institute (TSE:4576), the current Revenue is 円91.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?
Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued.
The current stock price of 円75.00 is trading 10.3% above its estimated GF Value™ of 円68.02.
GuruFocus considers D. Western Therapeutics Institute to be Fairly Valued.
Key valuation signals for TSE:4576:
Revenue: 円91.59 Mil
GF Value™: 円68.02 vs. price of 円75.00 (10.3% above fair value)
No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
47GF Score
Get the complete analysis for TSE:4576
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4576 has been successfully added to your 
